CompletedPhase 2NCT02648581
Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease
Studying Behçet disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Principal Investigator
- Benjamin TERRIER, MD, PhDAssistance Publique - Hôpitaux de Paris
- Intervention
- Subcutaneous Ustekinumab(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2019
Study locations (1)
- Hôpital Cochin, Department of Internal Medicine, National Reference Center for Autoimmune and Systemic Diseases, Paris, Paris, France
Collaborators
URC-CIC Paris Descartes Necker Cochin
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02648581 on ClinicalTrials.govOther trials for Behçet disease
Additional recruiting or active studies for the same condition.